Artificial Blood Substitutes vs. Allogeneic Blood: Current Status

Artificial oxygen carriers (blood substitutes) are not standard of care. Allogeneic human blood transfusion remains the only widely available, regulated therapy for significant anemia/acute blood loss.

Categories of Blood Substitutes

  • Hemoglobin-Based Oxygen Carriers (HBOCs): Cell-free hemoglobin (bovine, human, recombinant) — polymerized, cross-linked, encapsulated. Examples: Hemopure (HbO₂ Therapeutics — approved in SA for acute anemia), PolyHeme, Hemolink, OxyVita. None FDA-approved for general use. Toxicity: NO scavenging → vasoconstriction, hypertension, MI, stroke; oxidative injury; short half-life (12–24 hrs).
  • Perfluorocarbon (PFC) Emulsions: Oxygen dissolves in PFC (Oxygent, Fluosol). No hemoglobin. Require high FiO₂. Limited O₂ capacity. Fluosol withdrawn; Oxygent failed Phase III.
  • Stem Cell-Derived RBCs: In clinical trials (RESTORE trial, UK) — not yet commercial.

Current Clinical Use

  • Jehovah's Witness patients refusing blood — compassionate use / clinical trial access.
  • Military / remote / disaster settings — logistical advantages (storage, typing).
  • Organ preservation (perfusion solutions).

Why Not Routine?

  • Safety signals (HBOCs: increased mortality/MI in meta-analyses).
  • Short duration (hours) vs. stored RBCs (42 days).
  • No coagulation factors, platelets, immune modulators.
  • Cost >> blood.
  • Regulatory hurdles (FDA requires mortality benefit or non-inferiority + safety).

Research continues: PEGylated Hb, Hb vesicles, gene-edited universal RBCs. Blood conservation (PBM — patient blood management) is current standard to reduce transfusion need.

Blood Disorders - Related Articles